Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CODIN: Oral Digoxin in NASH
NCT06588699Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Jun 2025
- Primary completion
- Jan 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of digoxin in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Yale University. Primary endpoint: Resolution of nonalcoholic steatohepatitis (NASH) without worsening of fibrosis at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
digoxin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06588699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588699.